We are live on ! Find out more
XFOR icon

X4 Pharmaceuticals
XFOR

98 hedge funds and large institutions have $58.9M invested in X4 Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 35 increasing their positions, 19 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

232% more call options, than puts

Call options by funds: $349K | Put options by funds: $105K

84% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 19

12% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 17

2% more funds holding

Funds holding: 96 → 98 (+2)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.03% less ownership

Funds ownership: 2.04% → 2.02% (-0.03%)

59% less capital invested

Capital invested by funds: $143M → $58.9M (-$84.2M)

Holders
98
Holders Change
+2
Holders Change %
+2.08%
% of All Funds
1.42%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
19
Increased
35
Reduced
19
Closed
17
Calls
$349K
Puts
$105K
Net Calls
+$244K
Net Calls Change
+$150K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$2.12M
2
KCM
Kingdon Capital Management
New York
+$1.25M
3
VCIM
Velan Capital Investment Management
Georgia
+$718K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$622K
5
KPF
K2 Principal Fund
Ontario, Canada
+$533K

Top Sellers

Rank Fund Capital Flow
1
APM
Avidity Partners Management
Texas
-$3.35M
2
Morgan Stanley
Morgan Stanley
New York
-$1.28M
3
SCM
Sio Capital Management
New York
-$1.19M
4
Goldman Sachs
Goldman Sachs
New York
-$968K
5
Citadel Advisors
Citadel Advisors
Florida
-$822K
Name Holding Trade Value Shares
Change 		Change in
Stake
PBM
101
Propel Bio Management
California
– -$744K -17,833 Closed
SAM
102
Simplify Asset Management
Nevada
– -$556K -13,333 Closed
RA
103
Royce & Associates
New York
– -$476K -11,412 Closed
GCP
104
GSA Capital Partners
United Kingdom
– -$446K -10,701 Closed
Amundi
105
Amundi
France
– -$97.6K -2,710 Closed
LIP
106
Lighthouse Investment Partners
Florida
– -$97.9K -2,347 Closed
AIG
107
American International Group
New York
– -$85.8K -2,058 Closed
Dimensional Fund Advisors
108
Dimensional Fund Advisors
Texas
– -$76.9K -1,843 Closed
Walleye Capital
109
Walleye Capital
New York
– -$66.1K -1,586 Closed
TSS
110
Two Sigma Securities
New York
– -$41K -984 Closed
SG Americas Securities
111
SG Americas Securities
New York
– -$29K -694 Closed
GC
112
Grimes & Company
Massachusetts
– -$20.9K -500 Closed
TCWM
113
Total Clarity Wealth Management
Illinois
– -$19K -456 Closed
SW
114
SVB Wealth
Massachusetts
– -$18.1K -433 Closed
CSS
115
Cubist Systematic Strategies
Connecticut
– -$652 -16 Closed
AWM
116
Avior Wealth Management
Nebraska
– -$30 -1 Closed
1 2 3 4
5

XFOR Hedge Fund Activity: Q2 2024 in Review

98 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q2 2024, worth a combined $58.9M — down 59% from $143M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new XFOR positions and 17 closed out — a net gain of 2 holders — while 35 added to existing stakes and 19 trimmed.

The largest buyer was BlackRock, adding an estimated $2.12M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $3.35M sold.

  • 98 institutional investors held X4 Pharmaceuticals (XFOR) as of Q2 2024, up from 96 in Q1 2024.
  • Funds reported $58.9M of X4 Pharmaceuticals stock for Q2 2024, down 59% quarter-over-quarter.
  • 19 funds opened new X4 Pharmaceuticals positions in Q2 2024 and 17 closed out, a net change of +2 holders.
  • The largest X4 Pharmaceuticals buyer in Q2 2024 was BlackRock, an estimated $2.12M added.
  • The largest X4 Pharmaceuticals seller in Q2 2024 was Avidity Partners Management, an estimated $3.35M sold.

Based on aggregated 13F filings for Q2 2024.